(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.73%) $79.57
(5.62%) $2.31
(1.33%) $2 353.10
(3.53%) $28.58
(0.85%) $993.00
(-0.30%) $0.927
(-0.21%) $10.87
(-0.22%) $0.798
(0.86%) $92.53
Quarter results today
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States...
Stats | |
---|---|
Šios dienos apimtis | 11 882.00 |
Vidutinė apimtis | 22 613.00 |
Rinkos kapitalizacija | 37.91M |
EPS | $0 ( 2024-03-28 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.700 |
ATR14 | $0.0600 (1.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-03 | Milligan Sandra | Buy | 30 000 | EMPLOYEE STOCK OPTION (RIGHT TO BUY) |
2024-04-01 | Milligan Sandra | Buy | 0 | |
2024-02-15 | Sandford Nicole | Buy | 30 000 | Employee stock option (right to buy) |
2024-02-14 | Hombeck Torsten | Buy | 20 000 | Employee stock option (right to buy) |
2024-02-14 | Merchant Minh Hoang | Buy | 11 000 | Employee stock option (right to buy) |
INSIDER POWER |
---|
97.47 |
Last 89 transactions |
Buy: 4 309 531 | Sell: 195 424 |
Aspira Women's Health Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Aspira Women's Health Koreliacija - Valiuta/Žaliavos
Aspira Women's Health Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $9.15M |
Bruto pelnas: | $5.26M (57.48 %) |
EPS: | $-1.810 |
FY | 2023 |
Pajamos: | $9.15M |
Bruto pelnas: | $5.26M (57.48 %) |
EPS: | $-1.810 |
FY | 2022 |
Pajamos: | $8.18M |
Bruto pelnas: | $4.32M (52.77 %) |
EPS: | $-41.66 |
FY | 2021 |
Pajamos: | $6.81M |
Bruto pelnas: | $3.06M (44.95 %) |
EPS: | $-0.280 |
Financial Reports:
No articles found.
Aspira Women's Health
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.